Heart failure & cardiomyopathies
Cost-Utility Analysis of Add-On Qili Qiangxin Capsules in Chronic Heart Failure with Reduced Ejection Fraction in China
Authors' conclusion
This cost-utility analysis suggested that adding QLQX capsules seems to be cost-effective of heart failure with a reduced ejection fraction patients from the healthcare payer's perspective in China. Future studies of QLQX capsules based on different economic systems and medical environments were also needed.
Study context
- Population
- Patients with heart failure with a reduced ejection fraction in China
- Comparison
- Adding Qili Qiangxin (QLQX) capsules to standard treatment versus standard treatment
- Outcome
- Mean total costs
- Follow-up
- 19-year lifetime horizon
Methodological detailsMarkov model, healthcare payer's perspective, 19-year lifetime horizon, 3-month cycle, discount rate of cost and utility 5%
- Markov model
- Healthcare payer's perspective
- 19-year lifetime horizon
- 3-month cycle
- Discount rate of cost and utility 5%
Main finding
As reported in the abstract
Further findings
QALYs · 19-year lifetime horizon
Incremental cost-utility ratio (ICUR)
- ICUR
- 57 381.85 CNY per QALY
- Willingness-to-pay threshold
- 89 358 CNY
- Lower than the willingness-to-pay threshold
Sensitivity analyses
- Adding QLQX capsules to standard treatment was preferred over standard treatment alone in the 1000 PSA samples at a willingness-to-pay threshold of 89 358 CNY
- 51.10%
- The one-way and probability sensitivity analyses showed that the results were robust
- The inputs with the largest impact on ICUR were the cardiovascular mortality in both groups
Original publication
Cost-Utility Analysis of Add-On Qili Qiangxin Capsules in Chronic Heart Failure with Reduced Ejection Fraction in China. ESC Heart Fail. Published 11 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →